Mobile: +61 428 816 751
Seqirus news releases
Update - PRODUCT DEFECT CORRECTION - PALEXIA® SR 100mg
In consultation with the Therapeutic Goods Administration (TGA), Seqirus is issuing a Product Defect Correction for PALEXIA® SR 100mg tablet lot 986P01.
PRODUCT DEFECT CORRECTION - PALEXIA® SR 100mg
In consultation with the Therapeutic Goods Administration (TGA), Seqirus is issuing a Product Defect Correction for PALEXIA® SR 100mg tablet lot 985P01.
Seqirus and Richter sign a license agreement for the commercialisation of a novel treatment for schizophrenia in Australia and New Zealand
Seqirus Pty Ltd (Seqirus) and Gedeon Richter Plc (Richter) today announced the signing of an exclusive license agreement to commercialise a novel antipsychotic in Australia and New Zealand.
New PNG Snakebite Project to Improve Access to Antivenoms
The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management system.
Australians unprepared for potential dangers of venomous creatures this summer
Seqirus launches #NoStingsSummer campaign encouraging Aussies to take care and watch out for bites and stings this summer
Seqirus launches first over-the-counter offering, Nervoderm®
Seqirus has entered the over-the-counter market for the first time with a new Schedule 2, medicated patch, Nervoderm®.
Seqirus Manufacturing Director Recognised at 2017 Women in Industry Awards
Lisa Lamb, Manufacturing Director for Products of National Significance at biopharmaceutical company Seqirus has been named winner of the Manufacturing Excellence category at the 2017 Women in Industry Awards hosted in Melbourne on Thursday 22 June.
Afluria Quad™ – a four strain flu vaccine manufactured in Australia is now available
A quadrivalent flu vaccine manufactured by Seqirus locally in Melbourne, Australia is available for the 2017 Australian flu season for adults aged 18 years and older.
CSL completes Novartis influenza vaccine business acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.
Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus.
CSL Acquires Exclusive Rights to Influenza Treatment
CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX).